Biofrontera Inc. (BFRIW) stock
BFRIWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRI
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30
$0.00+0.00 (0.00%)
Close on Oct 30, 2026Market cap $12.96MP/E –Yield –
Biofrontera free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Biofrontera's free cash flow for the twelve months ending Jun 30, 2026 was -$7.93M. For fiscal 2025 it was -$13.36M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.36M | – |
| FY2024 | Dec 31, 2024 | -$10.28M | – |
| FY2023 | Dec 31, 2023 | -$24.90M | – |
| FY2022 | Dec 31, 2022 | -$16.24M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$75.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.38M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.82M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.05M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.02M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.21M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.67M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.38M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.00M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.70M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.27M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.94M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.22M | – |